Welcome to the InSyBio blog

Featured

In InSyBio (Intelligent Systems Biology), we have developed an on-line suite of software tools which assists biology researchers in extracting valuable biological knowledge from experimental data. Our team comprises of four enthusiastic software engineering researchers (Christos, Kostas, Christos and Aigli)  with long year experience in the area of informatiion technology and specially bioinformatics. Our work is strongly supported by Dr. Mavroudi,  a highly experienced academician in the fields of Computational Intelligence and Bioinformatics.

Our research experience on methodologies and algorithms for mining and processing biological data concluded to the development of an integrated bioinformatics tool platform called InSyBio Suite. This platform consists of tools for providing integrated biological information from various sources, while at the same time it is empowered with robust, user-friendly and installation-free bioinformatics tools based on intelligent algorithms and methods. You can find more about InSyBio Suite by visiting our site http://www.insybio.com

In this blog, we indent to share with you our thoughts, knowledge as well as interesting announces referring to the world of bioinformatics. Feel free to contribute to this blog with comments or even articles with your fresh ideas or thoughts.

We welcome you to our blog!

The InSyBio team

A new tool for processing single cell RNA-sequencing data

Single-cell RNA-sequencing is a genomic approach for the detection and quantitative analysis of RNA molecules in biological samples and has been extremely successful in the past few years in studying the cell-composition of biological samples, exploring cell proliferation and cell migration mechanisms and providing another layer of information in addition to bulk-RNA sequencing technologies.The new version of InSyBio Suite includes a new functionality in the InSyBio ncRNAseq tool for streamlining and optimizing the processing of single cell RNA-sequencing data.

  • The pioneer InSyBio ncRNAseq tool allows performing the analysis from raw data simplifying the process and allowing it to be run by non-bioinformatics experts.
  • In addition to the standard preprocessing steps, InSyBio ncRNASeq provides tools for statistical analysis of the data, clustering and cluster annotation using an unbiased approach. Moreover, it is inteconnected with other tools of InSyBio Suite allowing for the interpretation and meta-analysis of the results.
  • It also provides all the required data visualization steps allowing for the generation of ridge-plots, dot-plots, feature-plots, UMAP and PCA plots.
  • This tool provides an automatically generated documentation describing all the steps of the analysis, methods and parameters used so that it can be used as is for scientific publications.

The Product Development Manager of InSyBio, Aigli Korfiati, stated that “During the past year, we have received a substantial ammount of requests for processing such data in Cancer, Cardiovascular and Neurodegenerative diseases applications. The analysis of scRNAseq data with existing tools is far from being standardized and there are many common mistakes made by inexperienced users. With the expansion of InSyBio ncRNAseq tool with the new functionality of processing scRNAseq data, we reassure that users will perform unbiased and optimized prosessing of their data and get the most out of them with high-quality figures and documentation that can be used as is for high impact scientific publications”.

Read more details about this tool in the updated InSyBio ncRNAseq’s user manual: https://www.insybio.com/manuals/InSyBio%20ncRNASeq%20Manual.pdf

InSyBio is offering a one-month free license to use InSyBio Suite including the new version of InSyBio ncRNAseq tool. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

«Experience needs time and time brings experience»

For many years internships offered by companies are carried οut by University undergraduate students in order to  acquire real-world experience that enables them to put everything they have learned into action. Since early July, I started my first internship and it is a lot more than I thought it would be — in the best way possible. 

My three-month internship took place in InSyBio, a start-up company in Patra, Greece. InSyBio is a global biotechnology company servicing molecular biology researchers in the academia, private research sector and pharmaceutical companies by offering tools for biomarker discovery, biological data management, secured storage and computational bio-data analysis. My duties involved implementing tasks both for social media management- content editing for online promotion of the company- and business development. I have also gained experience working on business plans and calculating comprehensive financial indices such as EBITDA, Return of Investment, Break even analysis etc, as well as, performing SWOT and other relevant analyses. Moreover, I have acquired know-how around different web and standalone tools for creating and managing marketing material. The person who helped me most about business and economics issues was the CEO of InSyBio Mr. Labros Digonis, an entrepreneurial manager with more than thirty years of experience in top-management positions in multibillion groups and as management consultant in several industries. He helped me understand in depth concepts and definitions from economy science and guided me to implement practical daily business work issues. Last but certainly not least, I would like to thank my supervisors C. Alexakos, A. Korfiati and K. Theofilatos provided me a helping hand to join the board smoothly, allowing me to participate in several meetings per week with the rest of the InSyBio team, investors and consultants. With them I collaborated on a daily basis for the work tasks and I was provided with the opportunity to express my personality and abilities in order to offer to the team.

I have been very impressed with everyone I have worked with! And I know that I would not have gotten as much experience as I have already if I were to be in a bigger company, where interns may not get the chance to be as hands-on as I have been able to. My internship has been a great start to enter the labor market, as it has given me more real-world experience and made me more capable to use the skills that I already have and gained into different businesses in various ways.

Luena Zyberi 

«Η εμπειρία που δημιουργείται μετά το πέρας της πρακτικής»

Η πρακτική άσκηση αποτελεί ανέκαθεν μια ευκαιρία για τους νέους σπουδαστές να έρθουν σε μια πρώτη επαφή με την πραγματικότητα του εργασιακού χώρου, μεταλαμπαδεύοντας την γνώση που έχουν αποκτήσει από την ακαδημαϊκή τους καριέρα και βοηθώντας τους να ξεκινήσουν ομαλά την επαγγελματική τους σταδιοδρομία. Εντός αυτής της συνθήκης, λοιπόν, βρέθηκα και εγώ, νέα απόφοιτος του τμήματος οικονομικών επιστημών του Πανεπιστημίου Πατρών έχοντας διεκπεραιώσει με επιτυχία την πρακτική μου άσκηση στην εταιρεία InSyBio, στην πόλη της Πάτρας, και  είμαι τώρα στην ευχάριστη θέση να μοιραστώ την εμπειρία μου.

Το έναυσμα, λοιπόν, της επαγγελματικής μου πορείας ξεκίνησε μέσα από την InSyBio, μια βιοτεχνολογική εταιρεία παγκόσμιας εμβέλειας με έδρα στην Ευρώπη και στις Η.Π.Α, παρέχει υπηρεσίες σε ερευνητές μοριακής βιολογίας στον ακαδημαϊκό χώρο, στον ιδιωτικό τομέα έρευνας και σε φαρμακευτικές εταιρείες. Ταυτόχρονα, η εταιρεία επικεντρώνεται, μέσω προηγμένων υπολογιστικών εργαλείων μεγάλων δεδομένων, στην ανακάλυψη βιοδεικτών για τον καρκίνο, τις νευροεκφυλιστικές ασθένειες και τη διατροφή. Δεν χρειάστηκε πολύ καιρό για να εξοικειωθώ όντας ένα νέο μέλος στην ομάδα, οι πρώτες μέρες ήταν αρκετές για να καταλάβω την φιλοσοφία και τους στόχους της εταιρείας, να γνωρίσω τους επιβλέποντες μου και να αναλάβω τα σκήπτρα για να προσφέρω στην εταιρεία μέσα από το δικό μου πρίσμα γνώσεων στον τομέα των οικονομικών. Η τρίμηνη αυτή εμπειρία σε συνθήκες πραγματικού εργασιακού χώρου και χρόνου μου έδωσαν την δυνατότητα να αναπτύξω σε μεγαλύτερο βαθμό τις δεξιότητες μου σε θέματα οργάνωσης, πειθαρχίας, συνέπειας και επαγγελματισμού και να αναπτύξω νέα προσόντα που είναι απαραίτητα για την άμεση προσαρμογή στην αγορά εργασίας. Μέσα από τον ρόλο μου ως διαχειρίστρια κοινωνικών μέσων δικτύωσης και περιεχομένου έμαθα να οργανώνω σε αυστηρό χρονικό πλαίσιο το περιεχόμενο διαδικτυακής προώθησης των προϊόντων της εταιρίας και να αναλάβω σε μεγάλο βαθμό την επιμέλεια της εικόνας της εταιρείας στο διαδικτυακό κοινό. Παράλληλα, διεκπεραιώνοντας τα καθήκοντα μου ως βοηθός/συνεργάτης επιχειρησιακής ανάπτυξης μπόρεσα να εφαρμόσω την γνώση που έλαβα από τις σπουδές μου στο οικονομικό κομμάτι. Αρωγός στην συγκεκριμένη αρμοδιότητα και σύμβουλος προσωπικής και επαγγελματικής εξέλιξης υπήρξε ο CEO της εταιρείας Κ.Λάμπρος Διγώνης. Ένα άτομο με πολύχρονη εμπειρία στον χώρο των επιχειρήσεων, διευθύνων σύμβουλος σε πολυεθνικές εταιρείες και άνθρωπος γεμάτος γνώσεις σε διαφορετικούς τομείς και ενδιαφέρουσες εμπειρίες. Με βοήθησε να καταλάβω έννοιες και ορισμούς που άπτονται στον οικονομικό κόσμο καθώς, επίσης, με καθοδήγησε να εκτελέσω εργασίες στο πρακτικό τους κομμάτι αποκτώντας έτσι μια εικόνα για το πως μια εταιρεία εξετάζει και πραγματοποιεί σε πραγματικό χρόνο οικονομικά ζητήματα. Τέλος, δεν θα μπορούσα να μην αναφέρω τους επιβλέποντες μου, Χ. Αλεξάκο, Α. Κορφιάτη και Κ. Θεοφιλάτο που ήταν υποστηρικτές στο πρώτο μου επαγγελματικό ξεκίνημα και ο καθένας τους ξεχωριστά με βοήθησε να ενταχθώ ομαλά στην ομάδα, να λειτουργήσω αποδοτικά στις εργασιακές απαιτήσεις της δουλειάς και να αναδείξω τις ικανότητες και δεξιότητες μου.

Συμπεραίνοντας, το ξεκίνημα αυτό ήταν μια καλή αφορμή να μου δώσει τροφή για σκέψη. Όπως για παράδειγμα, να αρχίσω να ψάχνω επαγγελματικές ευκαιρίες, να συναναστρέφομαι με στελέχη πλήρως καταρτισμένα και να μαθαίνω μονίμως νέα πράγματα, να είμαι ανοιχτή σε επαγγελματικές προτάσεις διότι ό,τι προκύπτει βάζει το μικρό του λιθαράκι στην σύνθεση της εμπειρίας μου και της προσωπικής εξέλιξης μέσα από την εργασία. Ευγνώμων που συνεργάστηκα με τα στελέχη της InSyBio, ενδιαφέρουσα εμπειρία και άνθρωποι με δίψα για μάθηση και για δουλεία!.

Λουένα Ζύμπερι

Optimized and automatized biomarker discovery and processing of biomedical data with InSyBio Pipelines

The new version of InSyBio Suite includes InSyBio Pipelines, a new tool for automatizing and optimizing the computational process for identifying biomarkers.

  • The pioneer InSyBio Pipelines tool allows performing the analysis from raw data until the final biomarkers and predictive models are found in one step simplifying the process and allowing it to be executed by non-machine learning or bioinformatics experts.
  • It also provides optimized sets of parameters and algorithms selected for all steps of the analysis alleviating the pain of the user to optimize them.
  • In an attempt to optimize performance and minimizes biases from manual tuning of parameter and algorithm selection we provide optimized sets of parameters and analysis pipelines for specific application domains: Cancer, Neurodegenerative Diseases and Nutrition. These optimized parameters have been inferred by applying InSyBio’s proprietary multi-objective optimization methodology to optimize the omics analysis and biomarker discovery pipelines maximizing their performance in golden standard datasets. For more details on this methodology refer to InSyBio’s patent application: Theofilatos, K., Alexakos, C., Korfiati, A., Dimitrakopoulos, C., & Mavroudi, S. (2018). U.S. Patent Application No. 15/837,407.
  • Among other improvements, this new version of InSyBio Suite, allows the use of deep learning methods for building machine-learning based diagnostic and prognostic models with the identified biomarkers.

The CEO of InSyBio, Labros Digonis, stated that “This new version of InSyBio Suite overcomes some major limitations of biomedical big data analytics and biomarker discovery and opens the road to establish it as the analysis platform of choice, ‘the SAP’ for Pharma and Nutrition Industries’ R&D. Reproducibility of biomarker discovery is now not a big issue while biomarker discovery and omics data analysis can now be done in a transparent and optimized way differently for the various application domains: Cancer, Neurodegenerative Diseases and Nutrition”.

InSyBio is offering a one-month free license to use InSyBio Suite including the new version of InSyBio Pipelines tool. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

Personalizing the treatment of Chronic Pain Patients using the Salonpas® Pain Relieving Patch and Interpretable Artificial Intelligence

Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives. In the meantime, the Chronic Pain condition is affecting the lives of millions of patients deteriorating their ability to perform everyday tasks, diminishing their performance in their work environment and, in general, reducing their satisfaction of life. InSyBio and Clarity Science LLC, capitalizing on their established collaboration, deployed an interpretable artificial intelligence approach to personalize the application of an alternative Chronic Pain treatment based on the Salonpas® Pain Relieving Patch and evaluated their results on a cohort of 186 pain patients. The main findings of this work include:

  • Machine learning models for the prediction of changes in total BPI Severity scores, total BPI Interference scores, and changes in the total drugs after Salonpas® Pain Relieving Patch treatment were developed with accuracy and correlation exceeding 90% and 0.4, respectively
  • Clearly defined groups of responders and non-responders to this topical analgesic treatment were identified: e.g. The Salonpas® Pain Relieving Patch seems to provide maximal benefits in patients who take high number of anti-inflammatory drugs, use Voltaren®, have pain in the lower extremities, do little or no heavy physical exercise, and have problems with their sleep.
  • Using the identified prediction models on another pain study (OPERA study, 688 participants) it was found that 62.3% of the responders of other topical analgesics treatments would show additional improvement using the Salonpas Patch.

Peter Hurwitz, President of Clarity Science states: “Being able to incorporate predictive analytics to the treatment decision process, using an artificial intelligence platform like Insybio’s, should allow clinicians and patients to choose, with greater accuracy, personalized and effective treatments that will achieve positive outcomes without needing to trial a medication. This will ultimately lead to a simpler treatment pathway across disciplines that improves patient care through focused prescribing, reduces cost, and limits unnecessary adverse events.”

This work will be presented at PAINWeek 2021, the National Conference on Pain for Frontline Practitioners, September 7-11, 2021, Las Vegas, USA. Stay tuned with our newsletter to be among the first who will get access to the web tool that will allow the personalization of Chronic Pain treatment with the Salonpas Pain Relieving Patch that will be launched in July 2021.

Read more details on this study in our recent publication:

Gudin J, Mavroudi S, Korfiati A., Dietze, D., & Hurwitz, P. H Personalized Pain Therapy: Artificial Intelligence (AI) Utilized to Predict Patient Response to OTC Topical Analgesics. Anesth Pain Res. 2021; 5 (1): 1-11. Correspondence: Peter Hurwitz, Clarity Science LLC.;750. (https://scivisionpub.com/pdfs/personalized-pain-therapy-artificial-intelligence-ai-utilized-to-predict-patient-response-to-otc-topical-analgesics-1651.pdf)

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, Clarity aspires to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide ( www.claritysciences.org ).

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com.

InSyBio joins Loyal VC program and receives initial investment

InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors.

InSyBio will benefit from active business development support and guidance as well as having access to various valuable resources and services as part of the Loyal VC program.

InSyBio’s CEO Labros Digonis stated: “with the Loyal VC program we shall speed up the completion of our open financing round and accelerate the accomplishment of both our business and technological targets, most important of which are:

  • The launching and commercialization of the InSyBio Precision Chronic Pain Treatment Tool
  • To continue improving the InSyBio Suite by incorporating our clients’ feedback and by integrating additional tools in it like Thematic platforms for Cancer, Neurodegenerative Diseases and Nutrition
  • And eventually to evolve at such a level where the InSyBio suite will be the platform of choice for the discovery of biomarkers from single and multi-omics data.” And finally he added “between Insybio and Loyal VC it surely begins an encouraging win-win situation”

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

For more News visit our InSyBio Blog.

About Loyal VC

Loyal VC operates a global startup index fund with over 160 investments across more than 38 countries. The fund is designed to minimize systemic bias inherent in the investment process, unlocking greater returns.  The Loyal Startup Index Fund has delivered strong returns since its launch in 2018, thanks to its collaborative, staged investment process, its network of over 400 advisors, and its global relationships with the Founder Institute, the world’s largest pre-seed accelerator, and INSEAD, rated the #1 non-US business school for unicorn founders by Pitchbook.  Loyal’s global start-up index fund is inclusive of a diverse, often mission-driven, group of entrepreneurs. To date over 30% of the portfolio have a woman CEO, almost 30% are from emerging markets, and around 80% address one or more of the United Nation’s Sustainable Development Goals (UNSDGs).  

For more information visit www.loyal.vc

Precision Chronic Pain Treatment Tool: a first-of-its-kind tool for personalizing treatment of Chronic Pain Patients

In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science LLC and developed a machine learning-based tool for predicting the response of chronic pain patients to 4 different non-opioid pain treatment formulations. This tool is capitalizing on InSyBio’s unique machine learning technology to develop machine learning models that are able to predict various response to treatment metrics (including pain severity and interference scales as well as reduction of total drugs) with an unprecedented accuracy. The accuracy of these models in predicting the changes in the response to treatment metrics exceeded 82% for all metrics in a cohort of more than 600 patients while 98.1% of the participants which were classified as responders to non-opioid treatments presented substantial improvement in all metrics in a follow-up after 3-6 months from baseline.

The Precision Chronic Pain Treatment Tool is a first-of-its-kind tool that is able to stratify chronic pain patients into individuals who will benefit from topical analgesics treatment and select the most suitable non-opioid treatment formulation for them using as input a combination of demographics, clinical characteristics and other responses to a simple questionnaire.

The first version of this tool is available for a free trial usage by clinicians treating Chronic pain patients (get it from here: https://pain.insybio.com/index.php?r=site/register ) offering them the following features:

  • Evaluation of chronic pain situation of patients through the completion of a user-friendly web form
  • Monitoring the progress of chronic pain patients over the time (trends, graphical representation of their clinical and demographics characteristics etc.)
  • Suggesting suitable patients for non-opioid treatments
  • Suggesting the best performing non-opioid treatment among 4 different formulations.

A simpler version of this tool is available for chronic-pain patients (get it from here: https://painpatient.insybio.com/index.php?r=site/registernew ) to allow them to identify if a non-opioid treatment is suitable for them and suggest them discussing additional therapeutic options with their physician.

In the next few months this tool will be expanded with additional non-opioid formulations and treatments (such as pain patches), with more specialized versions for specific chronic pain etiologies, such as Osteoarthritis and Rheumatoid Arthritis, and incorporating biomarkers to improve the predictive accuracy of the utilized prognostic models.

Peter Hurwitz, President of Clarity Science states: “Through their predictive analytic and artificial intelligence algorithms, the team at InSyBio has developed a simple and unique tool that will allow patients and clinicians the ability to identify suitable treatments, and more importantly, treatments that will predict the likelihood of response prior to the patient beginning that treatment. Identifying treatments that may generate a positive outcome prior to prescribing is very exciting as it will cut down on unnecessary treatment trials, adverse events and side effects, time for a patient to feel relief, and cost, just to name a few advantages. With so many treatment options available, anything that may help in identifying the best approach upfront will be welcomed by the healthcare community and patients.”

Seferina Mavroudi, Chief Scientific Officer of InSyBio states: “Our tool is based on a Sophisticated, Interpretable Machine Learning approach to provide health care providers with a high accuracy yet trustable and transparent decision aid. Leveraging the power of AI in this way, I think we have arrived at the future of medical decision making.”

Aigli Korfiati, product development manager of InSyBio states: “Years of teamwork in building sophisticated ΑΙ have now met a huge medical need. Identifying the most beneficial treatment for each chronic pain patient is now possible and straightforward. You answer the questions in our web tool and simultaneously you get the results! Our product development team worked hard towards this goal achieving to optimize the user experience of both clinicians and patients.”

Find out more details about the tool as well as its user guide in: https://insybio.com/pain_tool.html

Read more details on the data used for the development of this tool in our recent publication:

Gudin, J., Mavroudi, S., Korfiati, A., Theofilatos, K., Dietze, D., & Hurwitz, P. (2020). Reducing opioid prescriptions by identifying responders on topical analgesic treatment using an individualized medicine and predictive analytics approach. Journal of pain research13, 1255.

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, Clarity aspires to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide (www.claritysciences.org).

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com .

JSS forms strategic partnership with InSyBio to pioneer precision medicine innovation in clinical trials

In a bold approach to revolutionize a vital part of the pharmaceutical/nutraceutical industry and change the stagnant norm that is the clinical trial process, JSS Medical Research Inc. has strategically partnered with InSyBio, a leading bioinformatics company, to drive desperately needed transformation. With credit to Axios Investments Corporation for facilitating the partnership, InSyBio and JSS will closely collaborate on both pre- and post-approval studies that will be aimed at reducing time and costs for treatment approval but also ensure that they are safe and effective in the real-world setting.

As the largest Canadian-owned CRO and with an expansive presence internationally, JSS has positioned themselves as a frontrunner in the health research space and constantly pursues a superior methodology in evaluation of health care. Foreseeing the shift in industry to a precision medicine approach with increased focus on real-world-evidence, JSS will collaborate with InSyBio whose biomarker discovery and machine learning technology allows for targeted patient selection, marked risk and cost reduction which will greatly improve the probability of success in clinical trials while at the same time improving patient care in the real-world setting. Through this partnership with InSyBio, JSS has now greatly strengthened their portfolio of services by providing their clients with the tools to:

  • Identify and prioritize potential drug candidates and method to optimize the signal detection in clinical trials
  • Apply a biomarker discovery component in the clinical trials process to maximize the probability of success through more targeted patient stratification
  • Provide prognostic biosignatures and machine learning models for patient stratification and outcome endpoint prediction allowing for a precision medicine application of drugs and therapies
  • Identify the profile of responders and non-responders not covered by a specific drug, revealing new marketing opportunities for new drugs

“We at JSS look forward to enhancing the service offering we are providing to clients with the unique analytical skills and results offered by InSyBio. We believe this brings clinical research and the resulting data analysis into the modern AI age and advanced stage where better faster more accurate results in the clinical research process” stated JSS CEO & CSO, Dr. John Sampalis.

Labros Digonis, InSyBio’s CEO noted “This groundbreaking partnership with JSS will help to set an important precedent for all future clinical trials and raise the bar for measuring success. The expansion of JSS’ market reach combined with InSyBio’s trail-blazing analytics, applicable at all stages of clinical trials, empowers top pharma with optimal patient selection, minimized risk of trial failure and enables a considerably shorter time-to-market at a much lower cost.”

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and personalized Nutrition.

For any further detail please contact our Director of Business Development, Mackenzie Hastings, at m.hastings@insybio.com

About JSS Medical Research Inc.:  JSS Medical Research is a full‐service International Contract Research Organization (CRO) with its corporate office in Montreal, Canada and regional offices in Colombia, India and Poland.

The company offers comprehensive clinical trial management services from study design to publication of results, in Phase I‐IV trials across a broad range of therapeutic areas. With science and clinical epidemiological expertise at its core and early phase services of the highest quality adhering to industry standards, JSS Medical Research is a leader in Post‐Approval Clinical Epidemiology Studies (PACES) including Post‐Marketing Observational Studies, Health Outcomes Research (HEOR) and Health Economics. Currently, JSS Medical Research is conducting research studies in over 21 countries around the world for its clients that include the top 25 Pharmaceutical companies and Biotechnology/Device companies, worldwide.

For more information, visit www.jssresearch.com .

 About Axios Investments Corporation: Axios Investments Corporation is a commercial and investment firm based in Montreal, Canada that recognizes emerging opportunities in the health science an Artificial Intelligence (AI) sectors.

For more information, visit www.axiosinvestments.ca

InSyBio Suite V2.6 has been launched offering a unique user experience and allowing exploration of the “dark matter” transcriptomics datasets

The new version of InSyBio Suite enables the fast and accurate analysis of omics data by non-bioinformatics experts empowered with novel techniques to explore the dark matter of the transcriptomics data. This new version:

  • has a new user interface to optimize the user experience of our subscribers making complex omics and multi-omics data analysis accessible to non-bioinformatics experts
  • allows exploration of previously unmapped reads of RNA-sequencing experiments with ready to use, efficient pipelines
  • minimizes the time and cost of bioinformatics analysis and provides innovative bioinformatics analysis which maximizes the chances of approval in high impact factor journals
  • provides more interpretable bioinformatics analysis

InSyBio Suite version 2.6 has been officially launched as of Friday November 15th 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that “A significant amount of reads from RNA-seq experiments (usually 5%-50%) remains unexploited because they do not match to reference transcriptomes. Our new pipeline not only enables exploiting this information with our advanced in-silico methods for the prediction and accurate classification of non-coding RNAs from these data but also reveals new potential functionalities for some of the non-coding RNAs, e.g. miRNAs which are also functioning as tRNA fragments“.

insybio suite screenshot

In addition to its new user interface, InSyBio Suite now offers the following unique features:

  • InSyBio ncRNAseq: A new non-coding RNA-seq pipeline [1] which enables the identification and functional characterization of non-coding RNAs from the “dark matter” of RNA-sequencing data consisting of the unmapped reads.
  • InSyBio BioNets: A new feature is included to allow for the automatic parsing and preprocessing of GSE files from Gene Expression Omnibus Database.
  • InSyBio Interact: A new functional enrichment module is included and empowered by our patent-pending technology [2] which has functionally characterized more than 90% of the human and mouse proteins and transcripts.

InSyBio’s CEO, Labros Digonis, stated that “The mission of InSyBio was always to bridge the gap of systems biology with translational research. We think that launching the new version of InSyBio Suite is a significant step in that direction as it now allows accessibility of complex bioinformatics tools and methods to molecular biologists, physicians and biotechnology researchers without requiring them to have a bioinformatics background or expensive computing infrastructures”.

InSyBio is offering a free, one-month license to use InSyBio Suite’s all new tools and functionalities. Request your free trial now by completing a simple form at: https://www.insybio.com/request.html .

The new version of InSyBio Suite will be presented by our Product Development Manager, Miss Aigli Korfiati, at the 14th annual HSCBB conference (HSCBB19 – https://sites.google.com/site/hscbb19/) which will take place at the FORTH/ICE-HT Conference Center, on December 8-10, 2019 in Patra, Greece

  1. Theofilatos, K., Alexakos, C., Korfiati, A., Dimitrakopoulos, C., & Mavroudi, S. (2018). U.S. Patent Application No. 15/837,407.
  2. Theofilatos, K., Dimitrakopoulos, C., Mavroudi, S., Korfiati, A., & Alexakos, C. (2017). U.S. Patent Application No. 15/361,461.

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio showcasing its breakthrough technology in investment Community of Texas

ISyBio is showcasing as one of 7 prestigious companies during The International Accelerator’s Demo Day taking place October 22nd, 2019 at 4:30pm.

As one of the leading companies in targeted biomarker discovery, InSyBio is revolutionizing both the medical and food/nutrition research fields. We drive innovation in both clinical trials and drug discovery through our proprietary analysis approach and have been validated through numerous pilot projects and high-level publications in areas such as Cancer, Nutrition and Neurodegenerative diseases. Bellow follows an indicative list of our latest press releases:

To continue this success, InSyBio is seeking a round A of investment money ($2.0m) to:

  • Accelerate the commercialization of InSyBio research tools
  • Commercialize own identified biomarkers through diagnostic and prognostic tests for key diseases (e.g. Stroke, Brain Tumors, Nutrition etc.)
  • Continue R&D
  • Establish the lab infrastructure for biomarkers.
  • Further penetrate US market and reach the 500,000 target labs (pharma, research, nutrition etc.)

Demo Day Agenda:

4:30pm – 5:30pm: Networking and Refreshments

5:30pm – 7:30pm: Live Pitching

7:30pm – 8:00pm: Networking and Closing Remarks

Address: 8121 Bee Caves Rd. Austin, TX. 78747

If you are interested in attending to this event please RSVP to our Director of Business Development, Mackenzie Hastings, no later than October 18th at m.hastings@insybio.com

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About International Accelerator: The International Accelerator is the only U.S. accelerator focused solely on investing in companies with non-U.S. citizen founders. IA provides access to seed funding, quality mentors, and services foreign-born entrepreneurs need to scale up their businesses in the United States. The International Accelerator is more than an accelerator program. It is a trusted co-founder for stateside ventures and dedicated to helping non-U.S. citizen entrepreneurs set up their U.S. company, give it an “American look and feel,” and lay a sturdy foundation to build a global business. The experienced team leverages years of international business, design, and entrepreneurial expertise, as well as access to industry experts, active investors and potential customers. At IA, the goal is to bring startups in and send them out with impressive products and the capability to stand on their own feet. Being entrepreneurs themselves, they clearly know the hardships and worries of the startup process. Apart from money, IA is always available to give the help customized for the founder, so they can focus on their product and developing their vision for the company.